A -enriched fraction of Bryophyllum pinnatum inhibits human myometrial contractility in vitro

Santos, Sara; Haslinger, Christian; Kalic, K; Faleschini, MT; Mennet, Mónica; Potterat, Olivier; Mandach, U von; Hamburger, Matthias; Simões-Wüst, Ana Paula

doi:10.1055/s-0039-3399941

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this type of wholistic medicine, it is still often used for sleep and anxiety disorders [19] and, since the 1970s, for the treatment of preterm labour and other hyperactivity diseases [13]. In Switzerland, its use during pregnancy to prevent preterm uterus contractions is well established [20,21], and uterus-relaxant properties have been proven at both the tissue [22,23] and cell level [24,25]. Some clinical studies have revealed its potential in the treatment of sleep disorders, be they during pregnancy [26] or associated with other diagnoses [27,28].…”

Section: Introductionmentioning

confidence: 99%

Bryophyllum pinnatum and Improvement of Nocturia and Sleep Quality in Women: A Multicentre, Nonrandomised Prospective Trial

Mirzayeva

Forst

Passweg

et al. 2023

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Nocturia is a pathologic condition that significantly affects the quality of sleep. The aetiology of nocturia is multifactorial, and the evidence available on its management remains limited. Besides behavioural measures, validated pharmaceutical treatment options exist but are, however, associated with marked side effects. Prospective clinical studies with tablets prepared from the leaf press juice of the plant Bryophyllum pinnatum revealed a tendency towards reduction of micturition in patients with overactive bladder (OAB) and several improvements in sleep quality. These observations are in part supported by in vitro and in vivo data. In the present study, we investigated the effectiveness of Bryophyllum 50% chewable tablets in the treatment of nocturia and associated sleep disorders. Altogether, 49 women with idiopathic OAB and nocturia of ≥2 voids/night were treated with Bryophyllum 50% tablets for 3 weeks (350 mg chewable tablets, dosage 0-0-2-2 oral tablets; WELEDA AG, Arlesheim, Switzerland). Nocturia, voiding volumes at night (ml), quality of life, sleep quality, and daily sleepiness were assessed before and after treatment with a 3-day micturition diary, the International Consultation on Incontinence evaluating overactive bladder and related impact on quality of life (QoL) [ICIQ-OAB], the Pittsburgh Sleep Quality Index (PSQI), and the Epworth Sleepiness Scale (ESS), respectively. The age of the study population was 68.5 ± 11.6 y. After treatment, nocturia diminished from 3.2 ± 1.4 to 2.3 ± 1.3 ( P < 0.001 ) and the PSQI score decreased from 7.7 ± 3.7 to 6.6 ± 3.4 ( P = 0.004 ). Urgency, the ICIQ score, and the ESS lowered significantly, and the micturition volume showed a tendency to increase. No serious adverse drug reactions were reported, and compliance was good. The results show a beneficial effect on the nocturnal voids and sleep quality of women with OAB. Bryophyllum 50% tablets can be regarded as a well-tolerated alternative in the treatment of nocturia and broaden the repertoire of standard management.

show abstract